Moreover, by altering aptamers that target different cancer cells (e.g., Her2 positive breast cancer cells, triple negative breast cancer cells, non-small cell lung cancer cells, osteosarcoma cells, and so on), the personalized paclitaxel derivatives could be developed for the patients with the according cancer types. Here, ERBB2 is linked to cancer.